埃索美拉唑的作用与功效

Esomeprazole benefits:

Esomeprazole is a proton pump inhibitor. This proton pump inhibitor mainly acts on acid-producing B cells and hydrogen-potassium-ATP receptors, resulting in a reduction in acid secretion. Therefore, esomeprazole is mainly suitable for acid-related diseases, such as gastroesophageal reflux disease, chronic gastritis, peptic ulcers, including gastric ulcers, duodenal ulcers and bleeding caused by ulcers, as well as Zollinger syndrome.

In addition, esomeprazole can also be combined with antibiotics and agent B, which is what we call quadruple therapy, for the eradication treatment of Helicobacter pylori. Esomeprazole is a proton pump inhibitor commonly used in clinical practice. Generally speaking, it is relatively safe, but it can also have side effects. For example, rare reactions such as allergies can lead to dermatitis, rash, abdominal pain, constipation, and rarely, increased aminotransferases, etc.

What esomeprazole does:

Esomeprazole reduces gastric acid secretion through a specific targeting mechanism and is a specific inhibitor of proton pumps in parietal cells. The R-isomer and S-isomer of esomeprazole have similar pharmacodynamic properties.

Esomeprazole is a weak base, which is concentrated in the high-acid environment of the acid secretion microtubules of parietal cells and converted into an active form, thereby inhibiting the H+/K+-ATPase (proton pump) at this site, inhibiting both basic gastric acid secretion and stimulated gastric acid secretion. Esomeprazole should be taken and discontinued correctly according to the condition and under the guidance of a professional doctor to ensure medication safety.

Esomeprazole drug interactions:

The absorption of ketoconazole and itraconazole may be reduced during esomeprazole therapy. When used concomitantly with diazepam, citalopram, imipramine, clomipramine, phenytoin, etc., the dose of these drugs may need to be reduced. Therefore, it is recommended to monitor phenytoin plasma concentrations when esomeprazole is coadministered or discontinued during phenytoin therapy. No incompatibility.